Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.
Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.
Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.
Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.
RBC Capital analyst Gregory Renza maintains Perspective Therapeutics (AMEX:CATX) with a Outperform and lowers the price targ...
Oppenheimer analyst Jeff Jones maintains Perspective Therapeutics (AMEX:CATX) with a Outperform and lowers the price target ...
Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate o...
B of A Securities analyst Alec Stranahan initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Buy rating and an...
